Poolbeg Pharma PLC (POLBF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Poolbeg Pharma PLC (POLBF) trades at $0.0958 with AI Score 48/100 (Grade C). Poolbeg Pharma PLC is a clinical-stage pharmaceutical company focused on developing innovative treatments for infectious diseases. Market cap: $73.1M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for POLBF: POLBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates POLBF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
POLBF: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Poolbeg Pharma PLC (POLBF) Healthcare & Pipeline Overview
Poolbeg Pharma PLC is a clinical-stage biotech firm specializing in the development of innovative therapies for infectious diseases, leveraging advanced technologies and a promising product pipeline to address critical health challenges.
What Is the Investment Thesis for POLBF?
Poolbeg Pharma PLC presents a compelling investment thesis driven by its innovative pipeline and strategic focus on infectious diseases. The company's lead candidates, POLB 001 and POLB 002, are positioned to address significant market needs, particularly in the wake of global health challenges. The global influenza treatment market is projected to grow significantly, providing a robust opportunity for POLB 001, while the RNA-based immunotherapy market is expected to expand rapidly, enhancing the potential for POLB 002. Additionally, the company's access to advanced micro- and nanoencapsulation technology offers a competitive advantage in developing oral vaccine delivery systems. Poolbeg Pharma's commitment to leveraging artificial intelligence in drug discovery further enhances its value proposition, potentially leading to accelerated development timelines and reduced costs. However, investors should be aware of the inherent risks associated with clinical-stage biotech firms, including regulatory hurdles and market competition.
Based on FMP financials and quantitative analysis
POLBF Key Highlights
Market capitalization of $73.1M reflects the company's emerging status in the biotechnology sector.
- Beta of 1.82 indicates higher volatility compared to the overall market, characteristic of clinical-stage biotech firms.
- No dividend yield as the company reinvests in R&D for product pipeline advancement.
- Focus on infectious diseases positions Poolbeg Pharma in a critical and growing healthcare market.
- Innovative use of AI in drug discovery could lead to faster and more efficient development processes.
Who Are POLBF's Competitors?
POLBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRNA Moderna, Inc. | $139.86 | -19.80% | $55.5B | — |
| NVAX Novavax, Inc. | $8.31 | -5.46% | $1.37B | — |
| BNTX BioNTech SE | $113.12 | +21.96% | $28.4B | 59 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are POLBF's Key Strengths?
Innovative product pipeline targeting critical infectious diseases.
- Access to advanced technologies for drug delivery and discovery.
- Strong leadership with expertise in pharmaceutical development.
What Are POLBF's Weaknesses?
Limited operational history as a newly established company.
- Small employee base may limit scalability in development efforts.
- No revenue generation yet as products are still in development.
What Could Drive POLBF Stock Higher?
Clinical trial results for POLB 001 expected in Q4 2026.
- Development of POLB 002 with anticipated regulatory submissions in 2027.
- Expansion of the oral vaccine delivery platform technology in 2026.
- Collaboration with research institutions to enhance drug discovery capabilities.
- Presentation of data at industry conferences to attract potential partnerships.
What Are the Key Risks for POLBF?
Negative return on equity (-55.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and approval processes for clinical-stage products.
- Market competition from established pharmaceutical companies.
- Dependency on successful clinical trial outcomes for product viability.
- Economic downturns affecting funding and investment opportunities.
What Are the Growth Opportunities for POLBF?
- Growth opportunity 1: The global influenza treatment market is projected to reach $10 billion by 2028, driven by rising incidences of influenza and the need for effective therapies. Poolbeg Pharma's POLB 001 stands to capture significant market share as a novel p38 MAP Kinase inhibitor, particularly in the wake of increased public health awareness following pandemics.
- Growth opportunity 2: The RNA-based immunotherapy market is expected to grow exponentially, with a projected CAGR of 25% through 2027. Poolbeg Pharma's POLB 002, as a first-in-class intranasal immunotherapy, is well-positioned to capitalize on this trend by addressing respiratory viral infections, a key area of unmet need.
- Growth opportunity 3: The oral vaccine delivery platform utilizing micro- and nanoencapsulation technology has the potential to revolutionize vaccine administration. With a growing emphasis on patient compliance and ease of administration, this technology could tap into a market projected to exceed $5 billion by 2026.
- Poolbeg Pharma's POLB 003 aims to prevent Melioidosis, targeting a niche yet critical area within the vaccine landscape, potentially leading to substantial market penetration.
- Growth opportunity 5: The integration of artificial intelligence in drug discovery is transforming the pharmaceutical landscape. Poolbeg Pharma's commitment to leveraging AI could lead to faster identification of viable drug candidates, reducing time to market and development costs, thus enhancing overall operational efficiency.
What Opportunities Does POLBF Have?
- Growing global demand for effective treatments for infectious diseases.
- Potential for strategic partnerships to enhance market reach.
- Expansion into emerging markets with unmet healthcare needs.
What Are POLBF's Competitive Advantages?
- Access to proprietary micro- and nanoencapsulation technology enhances product delivery.
- Strong focus on unmet medical needs in infectious diseases provides a competitive edge.
- Innovative use of artificial intelligence in drug discovery streamlines development.
- Diverse product pipeline reduces dependency on any single product's success.
- Strategic partnerships can enhance market access and resource sharing.
What Does POLBF Do?
Founded in 2021 and headquartered in London, United Kingdom, Poolbeg Pharma PLC operates as a clinical-stage pharmaceutical company dedicated to the development of treatments for infectious diseases. The company's innovative approach is exemplified by its diverse product pipeline, which includes POLB 001, a p38 MAP Kinase inhibitor aimed at treating severe influenza, and POLB 002, a first-in-class RNA-based immunotherapy designed for intranasal administration to combat respiratory viral infections. Additionally, Poolbeg Pharma is advancing POLB 003, an intramuscular vaccine targeting Melioidosis, a serious bacterial infection. Beyond these specific drug candidates, the company has secured licensed access to advanced micro- and nanoencapsulation technology, which is being utilized to create an oral vaccine delivery platform that effectively transports immune-stimulating antigens to targeted areas of the gut. Poolbeg Pharma also employs an artificial intelligence-powered program to enhance drug discovery processes and is developing a biomarker platform to identify individuals at risk of progressing to severe disease. The company’s sophisticated, model-derived vaccine discovery platform aims to uncover novel vaccine candidates, positioning Poolbeg Pharma as a forward-thinking player in the biotechnology sector.
What Products and Services Does POLBF Offer?
- Develops innovative treatments for infectious diseases.
- Focuses on clinical-stage pharmaceutical development.
- Holds a diverse product pipeline including vaccines and immunotherapies.
- Utilizes advanced micro- and nanoencapsulation technology for vaccine delivery.
- Employs artificial intelligence to enhance drug discovery processes.
- Aims to identify at-risk individuals through biomarker development.
How Does POLBF Make Money?
- Generates revenue through the development and licensing of pharmaceutical products.
- Focuses on clinical trials to validate product efficacy and safety.
- Explores partnerships and collaborations for technology access and market reach.
- Plans to monetize successful products through sales and licensing agreements.
- Invests in R&D to expand its product pipeline and technological capabilities.
What Industry Does POLBF Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in technology and increasing demand for innovative healthcare solutions. The global market for infectious disease therapeutics is expanding, with a projected CAGR of over 8% through the next five years. Poolbeg Pharma PLC is strategically positioned within this landscape, focusing on unmet medical needs in infectious diseases, particularly in the context of recent global health crises. The competitive landscape includes established pharmaceutical companies and emerging biotech firms, making innovation and speed to market critical for success.
Who Are POLBF's Key Customers?
- Healthcare providers looking for innovative treatment options.
- Pharmaceutical companies seeking licensing agreements for new therapies.
- Government health agencies focused on infectious disease prevention.
- Research institutions interested in collaboration for drug development.
- Patients requiring effective treatments for infectious diseases.
Forward Outlook
Wall Street analysts project Poolbeg Pharma PLC revenue of about $0 for fiscal 2026, with EPS near $-0.01.
POLBF Valuation & Market Position
With a $73.1M market cap, Poolbeg Pharma PLC sits in the micro-cap segment of the market. Relative to its peer group, POLBF's quantitative score of 48/100 is below the peer average of 72/100.
Key Financial Metrics
Return on equity for Poolbeg Pharma PLC stands at -55.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -57.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.17 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Poolbeg Pharma PLC's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 17.94 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Poolbeg Pharma PLC has missed Wall Street's EPS estimate in 0 of its last 3 reported quarters — a recurring pattern of falling short of estimates.
Company Profile
Poolbeg Pharma PLC operates in the Biotechnology industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Jeremy Skillington. POLBF has traded publicly since 2022.
POLBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- The recent insider buying suggests those in the know see value, mirroring situations like company X in 2017 when similar activity preceded a rally.
- Community sentiment seems to be shifting positively, with more users discussing potential catalysts, reminiscent of the early buzz around company Y before their breakthrough announcement.
- The overall market perception of the sector is improving, creating a tailwind for companies like Poolbeg, similar to the renewable energy sector's rise in 2020.
- Poolbeg's recent strategic partnerships are being viewed favorably, suggesting a stronger foothold in the market, much like company Z's collaborations that led to increased market share.
Bear Case
- Increased chatter about potential regulatory hurdles could dampen enthusiasm, akin to the concerns surrounding company A's product approval delays.
- Some community members are expressing skepticism about the company's long-term strategy, echoing the doubts that plagued company B before their restructuring.
- Recent market developments indicate increased competition in Poolbeg's niche, potentially squeezing margins, just as happened with company C after new entrants emerged.
- Despite some positive sentiment, there's still a significant segment of the community unconvinced about the company's ability to execute its plans, similar to the initial reaction to company D's ambitious roadmap.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
POLBF Latest News
No recent news available for POLBF.
POLBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for POLBF.
Price Targets
Wall Street price target analysis for POLBF.
POLBF MoonshotScore
What does this score mean?
The MoonshotScore rates POLBF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jeremy Skillington
CEO
Jeremy Skillington has extensive experience in the pharmaceutical and biotechnology sectors, having held various leadership roles in both public and private companies. He has a strong background in drug development and commercialization, with a focus on innovative therapies. Jeremy holds a PhD in Molecular Biology and has been instrumental in building teams and driving strategic initiatives in his previous roles.
Track Record: Under Jeremy's leadership, Poolbeg Pharma has successfully developed a robust pipeline of product candidates and secured licensing agreements for advanced technologies. His strategic vision has positioned the company to capitalize on emerging opportunities in the biotechnology sector.
POLBF OTC Market Information
The OTC Other tier represents stocks that are not listed on major exchanges like NYSE or NASDAQ, often including smaller or emerging companies. This tier typically has less stringent reporting requirements, which can lead to higher risk and lower liquidity compared to listed stocks.
- OTC Tier: OTC Other
- Lower visibility and recognition compared to companies listed on major exchanges.
- Potential for higher volatility due to limited trading volume.
- Regulatory risks associated with OTC stocks and compliance requirements.
- Review available financial statements and disclosures.
- Assess the company's product pipeline and clinical trial status.
- Investigate management's track record and industry experience.
- Evaluate the competitive landscape and market positioning.
- Monitor news and developments related to regulatory approvals.
- Incorporated in the UK with a focus on innovative healthcare solutions.
- Active engagement in clinical trials and product development.
- Partnerships with reputable organizations in the biotechnology sector.
What Investors Ask About Poolbeg Pharma PLC (POLBF) — Healthcare
What does the AI Score mean for POLBF?
POLBF holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Poolbeg Pharma PLC is a clinical-stage pharmaceutical company focused on developing innovative treatments for infectious diseases. With a robust pipeline including RNA-based immunotherapies …
What does Poolbeg Pharma PLC do?
Poolbeg Pharma PLC is a clinical-stage pharmaceutical company focused on developing innovative treatments for infectious diseases. The company is advancing a diverse product pipeline that includes POLB 001, a p38 MAP Kinase inhibitor for severe influenza, POLB 002, an RNA-based immunotherapy for respiratory infections, and POLB 003, a vaccine for Melioidosis. Poolbeg also utilizes cutting-edge technologies such as micro- and nanoencapsulation for vaccine delivery and artificial intelligence for drug discovery.
How does Poolbeg Pharma PLC navigate regulatory approval processes?
Poolbeg Pharma PLC is committed to adhering to regulatory standards set by agencies such as the FDA and EMA. The company engages in rigorous clinical trials to demonstrate the safety and efficacy of its products, ensuring compliance with regulatory requirements. By maintaining transparency and open communication with regulatory bodies, Poolbeg aims to facilitate the approval process for its innovative therapies.
What are the main risks for POLBF?
Poolbeg Pharma PLC faces several risks typical of clinical-stage biotech companies. These include the potential for regulatory hurdles that could delay product approvals, market competition from established pharmaceutical firms, and the inherent uncertainty surrounding clinical trial outcomes. Additionally, as a newly established company, Poolbeg may experience challenges in securing funding and navigating market volatility.
What are the key factors to evaluate for POLBF?
Poolbeg Pharma PLC (POLBF) holds an AI score of 48/100 (low). Poolbeg Pharma PLC presents a compelling investment thesis driven by its innovative pipeline and strategic focus on infectious diseases. Not financial advice.
How frequently does POLBF data refresh on this page?
POLBF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven POLBF's recent stock price performance?
Poolbeg Pharma PLC (POLBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline targeting critical infectious diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider POLBF overvalued or undervalued right now?
Poolbeg Pharma PLC (POLBF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research POLBF before investing?
Before investing in Poolbeg Pharma PLC (POLBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information as of June 2026.